Does Collaboration between General Practitioners and Pharmacists Improve Risk Factors for Cardiovascular Disease and Diabetes? A Systematic Review and Meta-Analysis
- PMID: 36846722
- PMCID: PMC9951619
- DOI: 10.5334/gh.1184
Does Collaboration between General Practitioners and Pharmacists Improve Risk Factors for Cardiovascular Disease and Diabetes? A Systematic Review and Meta-Analysis
Abstract
Objective: To assess whether inter-professional, bidirectional collaboration between general practitioners (GPs) and pharmacists has an impact on improving cardiovascular risk outcomes among patients in the primary care setting. It also aimed to understand the different types of collaborative care models used.
Study design: Systematic review and Hartung-Knapp-Sidik-Jonkman random effects meta-analyses of randomised control trials (RCTs) in inter-professional bidirectional collaboration between GP and pharmacists assessing a change of patient cardiovascular risk in the primary care setting.
Data sources: MEDLINE, EMBASE, Cochrane, CINAHL and International Pharmaceutical Abstracts, scanned reference lists of relevant studies, hand searched key journals and key papers until August 2021.
Data synthesis: Twenty-eight RCTs were identified. Collaboration was associated with significant reductions in systolic and diastolic blood pressure (23 studies, 5,620 participants) of -6.42 mmHg (95% confidence interval (95%CI) -7.99 to -4.84) and -2.33 mmHg (95%CI -3.76 to -0.91), respectively. Changes in other cardiovascular risk factors included total cholesterol (6 studies, 1,917 participants) -0.26 mmol/L (95%CI -0.49 to -0.03); low-density lipoprotein (8 studies, 1,817 participants) -0.16 mmol/L (95%CI -0.63 to 0.32); high-density lipoprotein (7 studies, 1,525 participants) 0.02 mmol/L (95%CI -0.02 to 0.07). Reduction in haemoglobin A1c (HbA1C) (10 studies, 2,025 participants), body mass index (8 studies, 1,708 participants) and smoking cessation (1 study, 132 participants) was observed with GP-pharmacist collaboration. Meta-analysis was not conducted for these changes. Various models of collaborative care included verbal communication (via phone calls or face to face), and written communication (emails, letters). We found that co-location was associated with positive changes in cardiovascular risk factors.
Conclusion: Although it is clear that collaborative care is ideal compared to usual care, greater details in the description of the collaborative model of care in studies is required for a core comprehensive evaluation of the different models of collaboration.
Keywords: allied health; cardiovascular disease; collaboration; general practitioner; pharmacist; primary care.
Copyright: © 2023 The Author(s).
Conflict of interest statement
The authors have no competing interests to declare.
Figures



Similar articles
-
General practitioner and pharmacist collaboration: does this improve risk factors for cardiovascular disease and diabetes? A systematic review protocol.BMJ Open. 2019 Aug 5;9(8):e027634. doi: 10.1136/bmjopen-2018-027634. BMJ Open. 2019. PMID: 31383700 Free PMC article.
-
Psychological interventions to improve self-management of type 1 and type 2 diabetes: a systematic review.Health Technol Assess. 2020 Jun;24(28):1-232. doi: 10.3310/hta24280. Health Technol Assess. 2020. PMID: 32568666 Free PMC article.
-
Impact of the pharmacist-led intervention on the control of medical cardiovascular risk factors for the primary prevention of cardiovascular disease in general practice: A systematic review and meta-analysis of randomised controlled trials.Br J Clin Pharmacol. 2020 Jan;86(1):29-38. doi: 10.1111/bcp.14164. Epub 2020 Jan 3. Br J Clin Pharmacol. 2020. PMID: 31777082 Free PMC article.
-
Effects of telephone call intervention on cardiovascular risk factors in T2DM: A meta-analysis.J Telemed Telecare. 2019 Feb;25(2):93-105. doi: 10.1177/1357633X17745456. Epub 2017 Dec 11. J Telemed Telecare. 2019. PMID: 29228855
-
Vegan dietary pattern for the primary and secondary prevention of cardiovascular diseases.Cochrane Database Syst Rev. 2021 Feb 25;2(2):CD013501. doi: 10.1002/14651858.CD013501.pub2. Cochrane Database Syst Rev. 2021. PMID: 33629376 Free PMC article.
Cited by
-
Development, Pilot, and Evaluation of a Qualitative Documentation Tool for Pharmacists to Share High Impact Patient Intervention Stories.Innov Pharm. 2024 Aug 21;15(3):10.24926/iip.v15i3.5772. doi: 10.24926/iip.v15i3.5772. eCollection 2024. Innov Pharm. 2024. PMID: 39483506 Free PMC article.
-
Empowering Pharmacists in Type 2 Diabetes Care: Opportunities for Prevention, Counseling, and Therapeutic Optimization.J Clin Med. 2025 May 29;14(11):3822. doi: 10.3390/jcm14113822. J Clin Med. 2025. PMID: 40507585 Free PMC article.
-
Patients' and providers' perspectives of a dose administration aid strategy to improve cardiovascular disease prevention in Australian primary healthcare.BMC Health Serv Res. 2025 Feb 21;25(1):293. doi: 10.1186/s12913-025-12391-8. BMC Health Serv Res. 2025. PMID: 39984999 Free PMC article. Clinical Trial.
References
-
- Australian Institute of Health and Welfare. Cardiovascular disease: Australian facts. Cardiovascular disease series Cat no CVD 53. Canberra: AIHW; 2011.
-
- World Health Organization. Prevention of cardiovascular disease: guidelines for assessment and management of total cardiovascular risk; 2007.
-
- Country statistics and global health estimates by WHO and UN partners. Australia: WHO statistical profile; 2015. Retrieved from: http://who.int/countries/aus/en/.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical